Novel mechanistic insights into the anti-cancer mode of arsenic trioxide.
Arsenic, a naturally-occurring toxic element, and a traditionally-used drug, has caught a great deal of attention from worldwide people due to its curable anti-cancer effect in patients with acute promyelocytic leukemia (APL). Among the arsenicals, arsenic trioxide (ATO) has been the most widely used anti-cancer drug. Recent advances in cancer therapeutics have led to a paradigm shift away from the traditional cytotoxic drugs towards the targeting of proteins closely associated with driving the cancer phenotype. Due to the diverse anti-cancer effects of ATO on different types of malignancies, numerous studies have made effort to uncover the underlying ATO-induced tumor suppressive effect. From in vitro cellular model to clinical settings, ATO has been extensively studied and the outcomes of studies have opened a door to establish improved molecular-targeted therapy for the treatment of cancer. The efficacy of ATO has been further augmented by the combination with other drugs. In this review, we discuss the recent arsenic-based therapies to treat cancer and summarize the novel underlying molecular mechanism of the anti-cancer effects of ATO.